Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | NOS3 | P29474 | 1/20 | 0.53 |
| ▸ | NOS1 | P29475 | 1/20 | 0.53 |
| ▸ | NOS2 | P35228 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24663840 | 0.94 | HRH3 (0.59) | HRH3SMN1; SMN2ALDH1A1TSHRNOS3 | |
| SCHEMBL25443762 | 0.87 | SIGMAR1 (0.52) | HRH3SMN1; SMN2ALDH1A1LMNAPOLB | |
| SCHEMBL18942427 | 0.85 | HRH3 (0.59) | HRH3SMN1; SMN2ALDH1A1TSHRNOS3 | |
| SCHEMBL15467001 | 0.84 | HRH3 (0.87) | HRH3SMN1; SMN2ALDH1A1NOS3NOS1 | |
| SCHEMBL14652036 | 0.83 | NCF1 (0.65) | HRH3SMN1; SMN2ALDH1A1TSHRNOS1 | |
| SCHEMBL20013868 | 0.83 | HRH3 (0.65) | HRH3SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL4547887 | 0.82 | HRH3 (0.65) | HRH3SMN1; SMN2ALDH1A1NOS3NOS1 | |
| SCHEMBL30596572 | 0.81 | HRH3 (0.69) | HRH3SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL19441582 | 0.81 | HRH3 (0.62) | HRH3SMN1; SMN2ALDH1A1NOS3NOS1 | |
| SCHEMBL19441606 | 0.81 | HRH3 (0.62) | HRH3SMN1; SMN2ALDH1A1NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365568-A1 | PLK1 POLO BOX DOMAIN INHIBITORS AND METHOD OF TREATING CANCER | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-11-16 | — | — | US | disclosed |
| US-10787482-B2 | Epoxyketone compounds for enzyme inhibition | Centrax International Inc. (US) | 2020-09-29 | — | — | US | disclosed |
| US-10640533-B2 | Epoxyketone compounds for enzyme inhibition | CENTRAX INTERNATIONAL, INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20200087343-A1 | EPOXYKETONE COMPOUNDS FOR ENZYME INHIBITION | CENTRAX INTERNATIONAL, INC. (US) | 2020-03-19 | — | — | US | disclosed |
| US-20170158734-A1 | EPOXYKETONE COMPOUNDS FOR ENZYME INHIBITION | CENTRAX INTERNATIONAL, INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-20170158734-A1 | EPOXYKETONE COMPOUNDS FOR ENZYME INHIBITION | CENTRAX INTERNATIONAL, INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-8835441-B2 | Heterobicyclic metalloprotease inhibitors | AMGEN INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20080221083-A1 | Heterobicyclic metalloprotease inhibitors | HOCHGURTEL MATTHIAS | 2008-09-11 | — | — | US | disclosed |
| US-20080221092-A1 | Heterobicyclic metalloprotease inhibitors | BLUHM HARALD | 2008-09-11 | — | — | US | disclosed |
| US-20080221092-A1 | Heterobicyclic metalloprotease inhibitors | BLUHM HARALD | 2008-09-11 | — | — | US | disclosed |
| US-20080161300-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155737-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155737-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155737-A1 | Heterobicyclic metalloprotease inhibitors | ADAMTS4, ADAMTS1, ADAMTS5 | HRH3 1912/4885SMN1; SMN2 4368/4885ALDH1A1 3954/4885 |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | MMP13, TIMP3, MMP3 | HRH3 1831/4885SMN1; SMN2 4594/4885ALDH1A1 1806/4885 |
| US-20080221083-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, MMP3, TIMP3 | HRH3 1828/4885SMN1; SMN2 4554/4885ALDH1A1 1907/4885 |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | MMP13, TIMP3, MMP3 | HRH3 1831/4885SMN1; SMN2 4594/4885ALDH1A1 1806/4885 |
| US-20080161300-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | HRH3 1831/4885SMN1; SMN2 4594/4885ALDH1A1 1806/4885 |
| US-10787482-B2 | Epoxyketone compounds for enzyme inhibition | PSMD10, PSMC1, PSMB10 | HRH3 4156/4885SMN1; SMN2 1323/4885ALDH1A1 1707/4885 |
| US-10640533-B2 | Epoxyketone compounds for enzyme inhibition | PSMD10, PSMC1, PSMB10 | HRH3 4156/4885SMN1; SMN2 1323/4885ALDH1A1 1707/4885 |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | HRH3 1831/4885SMN1; SMN2 4594/4885ALDH1A1 1806/4885 |
| US-20170158734-A1 | EPOXYKETONE COMPOUNDS FOR ENZYME INHIBITION | PSMD10, PSMC1, PSMB10 | HRH3 4156/4885SMN1; SMN2 1323/4885ALDH1A1 1707/4885 |
| US-20200087343-A1 | EPOXYKETONE COMPOUNDS FOR ENZYME INHIBITION | PSMD10, PSMC1, PSMB10 | HRH3 4156/4885SMN1; SMN2 1323/4885ALDH1A1 1707/4885 |
| US-20230365568-A1 | PLK1 POLO BOX DOMAIN INHIBITORS AND METHOD OF TREATING CANCER | PLK1, PLK4, BUB1B | HRH3 3186/4885SMN1; SMN2 2933/4885ALDH1A1 4253/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | HRH3 1831/4885SMN1; SMN2 4594/4885ALDH1A1 1806/4885 |
| US-20080221092-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, MMP3, TIMP3 | HRH3 1736/4885SMN1; SMN2 4507/4885ALDH1A1 1875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.